Some new 3H-quinazolin-4-one derivatives were synthesised and screened for anticancer, antiphospholipases, antiproteases, and antimetabolic syndrome activities. Compound 15d was more potent in reducing the cell viabilities of HT-29 and SW620 cells lines to 38%, 36.7%, compared to 5-FU which demonstrated cell viabilities of 65.9 and 42.7% respectively. The IC 50 values of 15d were $20 mg/ml. Assessment of apoptotic activity revealed that 15d decreased the cell viability by down regulating Bcl2 and BclxL. Moreover, compounds, 8j, 8d/15a/15e, 5b, and 8f displayed lowered IC 50 values than oleanolic acid against proinflammatory isoforms of hGV, hG-X, NmPLA 2, and AmPLA 2 . In addition, 8d, 8h, 8j, 15a, 15b, 15e, and 15f showed better anti-a-amylase than quercetin, whereas 8g, 8h, and 8i showed higher antia-glucosidase activity than allopurinol. Thus, these compounds can be considered as potential antidiabetic agents. Finally, none of the compounds showed higher antiproteases or xanthine oxidase activities than the used reference drugs.
Introduction
Colorectal cancer (CRC) is the third-most common cancer and the fourth-most common cause of cancer-related death worldwide 1 . One of the key features of cancer is deregulation of apoptosis of the altered cells 2 . Apoptosis is mediated by a complex network of BCL-2 family of proteins, comprising two types of proteins, namely anti-apoptotic proteins, which include Bcl2, BclxL, and Mcl-1, and pro-apoptotic proteins, which include Bax and Bak 3 . Hence, inhibiting the anti-apoptotic BCL-2 proteins can be established as a mechanism of anticancer defence for the treatment of CRC 4 .
Several in vitro and in vivo clinical studies have suggested a positive correlation between the activity of certain proteases, such as trypsin 5 , cathepsin B 6 , collagenases 7 , thrombin 8 , and neutrophil elastase 9 and colorectal carcinogenesis, invasion, proliferation, and metastasis.
Furthermore, three phospholipases, namely (hsPLA 2 -IIA), group V, and group X 10 are found to paly indirect pro-tumorigenic roles by promoting chronic inflammatory bowel diseases (IBD) that are common risk factors associated with CRC 11 . In addition, recent studies have linked the incidence of CRC to certain metabolic syndrome components, especially elevated plasma glucose (type 2 diabetes mellitus) 12 . Several enzymes are reported to be involved in glucose homeostasis, among them a-amylase, a-glucosidase 13 , and xanthine oxidase 14 . Hence, targeting these enzymes has high potential in preventing CRC.
The 3H-quinazolin-4-one scaffold is known to be an important building block of various bioactive natural products 15 . In addition to this, many marketed drugs or experimental drug candidates incorporate this pharmacophore as part of the overall topography of the molecules 16 such as ispinesib, nolatrexed, and raltitrexed (the anticancer agents); afloqualone with sedative and muscle relaxant effects, balaglitazone with antidiabetic activities, proquazone (as non-steroidal anti-inflammatory agent), and elinogrel (as reversible P2Y12 receptor antagonist) which is used for the treatment of acute coronary syndrome. Moreover, several new methodologies have been developed for the synthesis of 4-quinazolinone derivatives either using one pot multicomponent approaches 17 or via multistep routes for investigating their pharmacological potential as dual EGFR/HER2 inhibitors 18 , phosphoinositide 3-kinase inhibitors 19 , and as antihypertensive 20 , antioxidant 21 , anticonvulsant 22 , and anti-inflammatory 23 agents. Based on these observations, and in continuation to our ongoing research programme aims to identify new bioactive molecules 24, 25 herein, we report the synthesis, characterisation, and cytotoxicity screening (including evaluation of apoptotic activity), for a new series of 3H-quinazolin-4-one derivatives against HT-29 and SW620 cell lines derived from CRC. Furthermore, the inhibitory potentials of the synthesised compounds against certain phospholipases and proteases implicated in cancer and inflammatory disorders, in addition to a-amylase, a-glucosidase, and xanthine oxidase, managing metabolic syndrome are investigated with the aim of eradicating the risk factors for CRC or combatting the disease.
Materials and methods

Chemistry
The reactions were monitored and the purity of the final products was checked using thin layer chromatography (TLC) on pre-coated silica gel sheets (60 F254, Merck, Kenilworth, NJ). The developed plates were examined by exposure to ultraviolet light using VL-6.LC (254, 365 nm, 50/60 Hz). All the melting points were determined in open capillary tubes with a Gallenkamp melting point apparatus ( C). The infra-red (IR) spectra were recorded on a Perkin Elmer Fourier transform infra-red (FTIR) spectrophotometer (Spectrum BX 1000) in wave numbers (cm À1 ) with potassium bromide (KBr) discs. Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker NMR spectrometer: 1-Ascend 850 MHz for 1 H and 213 MHz for 13 C, or on 2-Avance 600 MHz for 1 H and 150 MHz for 13 C (Nuclear Magnetic Resonance Center, KAU, Jeddah, KSA), or on a Bruker Avance 500 spectrometer operating at 500 MHz for 1 H and 125 MHz for 13 C at 25 C (Research Unit, College of Pharmacy, Prince Sattam Bin Abdulaziz University, AlKharj, KSA), or on an Eclipse 300 FT NMR spectrometer operating at 300 MHz spectrometer for 1 H and at 75 MHz for 13 C at 25 C (KSU, Riyadh, KSA). The chemical shifts were expressed in (ppm) using tetramethylsilane as the internal standard; coupling constants (J) were expressed in Hz. Deuterochloroform (CDCl 3 ) was used as solvent. The splitting patterns (multiplicities) in 1 HNMR were designated as: singlet (s), broad singlet (br. s), doublet (d), double of doublet (dd), triplet (t), and multiplet (m). Mass spectra were recorded on Shimadzu Qp-2010 Plus mass spectrometer in ionisation mode: EI (Micro Analytical Center, Cairo University, Egypt were reported previously.
General procedure for the preparation of compounds 5a-c
32,33
A mixture of the appropriate 2-methyl-benzo[d] [1, 3] oxazin-4-one derivative 3a-c (0.003 mol) and 3,4,5-trimethoxyaniline 4 (0.003 mol, 0.55 g) was fused in oil bath at 200 C for 2 h. After cooling down the temperature to 100 C, 37% HCl (Conc) (3 ml) was added till all the material was dissolved completely. The reaction mixture was cooled down to room temperature and was made alkaline with diluted NaOH solution (25%). The crude precipitated solid in each case, was filtered, washed with water, dried, and recrystallised from ethanol to yield compounds 5a-c. Synthesis of Schiff's base derivatives (8a-j) 34 A mixture of 3-amino-2-methyl-3H-quinazolin-4-one derivatives 6a,b (0.002 mol) and the appropriate aromatic aldehyde 7a-e, namely, 2-naphthaldehyde, 4-(pyridin-2-yl) benzaldehyde, 3-methoxy-2-nitrobenzaldehyde, 4-formylbenzonitrile, and 1,1 0 -biphenyl]-4-carbaldehyde (0.002 mol) in absolute ethanol (20 ml) containing (3 ml) glacial acetic acid was heated under reflux for 10 h. The excess solvent was removed under reduced pressure. The obtained solid in each case was washed with water, air dried, and recrystallised from the appropriate solvent to obtain the corresponding Schiff's base. 
Beige powder (ethanol), yield (55%), mp 178-180 
Synthesis of (2-methyl-4-oxo-4H-quinazolin-3-yl)-carbamic acid isobutyl ester (10)
A mixture of 3-amino-2-methyl-3H-quinazolin-4-one 6a (0.0028 mol, 0.5 g) and isobutyl chloroformate 9 (13.6 equiv., 0.038 mol, 5.2 g, 4.94 ml) was refluxed for 10 h 35 . The excess reagent was evaporated under reduced pressure and the remaining residue was treated with diethyl ether. The precipitated solid was filtered, washed with water, and purified by recrystallisation from benzene to obtain the title compound as a beige powder with 50% yield, mp 168-170 C; v max (KBr)/cm À1 3223 (NH), 3080 
A mixture of 3-amino-2-methyl-3H-quinazolin-4-one 6a (0.0028 mol, 0.5 g) and N,N-dimethyl formamide dimethyl acetal 11 (5.39 equiv. 0.0151 mol, 1.79 g, 2 ml) in ethanol (15 ml) was refluxed for 2 h 36 . The excess solvent was removed under reduced pressure. The remaining solid was washed with n-hexane and recrystallised from ethanol to obtain the title compound as a yellow powder with 50% yield, mp 100-102 C; max (KBr)/cm À1 3010 Synthesis of 2-(4-chloro-benzylsulfanyl)-6-methyl-3-phenyl-3H-quinazolin-4-one (15a 31 , 15b) and 2-(4-oxo-3-phenyl-3,4-dihydro-quinazolin-2-ylsulfanyl)-acetamide derivatives (15c-f)
A mixture of the appropriate derivative of 2-mercapto-3-phenyl-3H-quinazolin-4-one (13a',b') (0.0018 mol) and 4-chlorobenzyl chloride 14a or chloroacetamide derivatives 14b,c 37, 38 (1 equiv., 0.0018 mol) and potassium carbonate (2.5 equiv., 0.0045 mol, 0.62 g) in dry acetone (20 ml) was refluxed for 6 h 39 . The hot reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The resulting solid in each case was washed with water, air dried, and recrystallised from ethanol to obtain compounds 15a-f.
2 -(4-Chloro-benzylsulfanyl)-6-methyl-3-phenyl-3H-quinazolin-4-one (15b) 
Biological evaluation
Cell culture Human CRC cell lines, HT-29 and SW620 cells were grown in RPMI (Invitrogen) containing 10% heat-inactivated foetal bovine serum, 100 mg/ml streptomycin, 100 units/ml penicillin and 2 mmol/l L-glutamine.
Cell viability assay
Cell viability was determined using the 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) MTT assay according to Mosmann 40 . 5-Fluorouracil (5-FU) was used as positive control. Briefly, after culturing cells in 96 well plates for 24 h, they were treated with different compounds (30 lg/ml) for 24 h. Freshly prepared MTT (5 mM) solutions were added to the cells and were further incubated for 2 h at 37 C in 5% CO 2 . One hundred microliters of dimethyl sulphoxide (DMSO) was added in each well to dissolve the formazan crystal, formed in the reaction during incubation by careful pipetting. The absorbance of the product was measured at 540 nm using a microplate reader. The experiments were performed in triplicate for each condition. The graph illustrates the mean and standard deviation (SD) values of three independent experiments. Cytotoxicity assay using the xCELLigence system The optimal seeding concentration for proliferation of HT-29 was determined. HT-29 cells (5000 cell in 150 ml medium/well) and SW620 cells (12,000 cell in 150 ml medium/well) were seeded in 16 well plates (E-plate 16-ACEA Biosciences Inc., San Diego, CA) as described in the xCELLigence Real Time Cell Analyzer (RTCA) DP instrument manual provided by the manufacturer. After 24 h, 20 and 40 mg/ml of compound 15d were added and the experiments were allowed to run for another 3 d. Baseline cell indexes were calculated for at least two measurements from three replicate experiments.
Western blotting
Whole cell lysates were prepared using radioimmunoprecipitation assay (RIPA) lysis buffer as described by Al-Khayal and co-workers 41 . Total protein concentration was determined using Bradford protein reagent (Bio-Rad, Hercules, CA). Soluble proteins were loaded on precast TGX gels and were analysed using immunoblotting with anti-Bcl2, anti-BclxL (dilution 1:1000; Santa Cruz Biotechnology, Dallas, TX), and anti-b-actin (1:10,000 Sigma, St. Louis, MO). Reactivity was detected using horseradish peroxidaseconjugated secondary antibodies and chemiluminescence by Clarity Western ECL substrate (Bio-Rad). Membrane was developed using C-Digit Blot Scanner (LI-COR, Hamburg, Germany).
In vitro evaluation of antiphospholipases activities
The inhibitory activities of the synthesised 3H-quinazolin-4-one derivatives against a group of phospholipases were investigated according to the method of De Aranjo and Radvany 42 using five sPLA 2 s: human group IIA (hG-IIA), human group V (hG-V), human group X (hG-X), Apis mellifera bee venom (AmPLA 2 ) and Naja mossambica mossambica sPLA 2 (NmPLA 2 ). Ten microliters of each sPLA 2 solution (20 lg/ml) was mixed with 10 ll of each compound at different concentrations (0-50 lg/ml) and the mixture was incubated for 20 min at room temperature. Then, 1 ml of the PLA 2 substrate (3.5 mM lecithin suspended in 100 mM NaCl, 10 mM CaCl 2 , 3 mM NaTDC, and 0.055 mM red phenol, pH 7.6) was added. The hydrolysis kinetics was followed spectrophotometrically for 5 min at 558 nm. The results were reported as the inhibition percentage that was calculated by comparison with a control experiment (absence of compound) and the IC 50 values were determined from the curve. Oleanolic acid (Sigma) was used as the positive control.
In vitro evaluation of antiproteases activities
The inhibitory effects of 21 3H-quinazolin-4-one derivatives on several available therapeutically important proteases such as cathepsin-B, collagenase, elastase, thrombin, and trypsin were investigated. The inhibition of the enzymes in the presence of test compounds was evaluated by adding different concentrations of each compound (0-75 lg/ml) to the respective reaction mixture, preincubating for 15 min and then measuring the remaining enzyme activity as previously described 43 . The protease inhibitory activity was expressed as inhibition percentage, which was determined by comparison with a control experiment. The results were expressed as IC 50 values that were determined from the standard curve. A protease inhibitor cocktail (Sigma) was used as the positive control.
In vitro inhibition of a-amylase activity The a-amylase inhibitory activity of the tested compounds was investigated according to the reported method by Subranian 44 . Briefly, 10 mL of a-amylase (3,3 U) (Sigma) was mixed with 10 ml of different concentrations (20-200 mg/ml) of each compound, the appropriate solvent, or quercetin (positive control), and incubated at 37 C for 5 min. After adding 180 ml of Labtest (amylase substrate), the samples were incubated for 8 min and the absorbance of first reaction was measured at 620 nm. Then, 100 ml of the reaction mixture was incubated for more five additional minutes at 37 C and the absorbance of the second reaction was measured. Labtest was diluted in distilled water (1:1) before being added to the microplate. The concentration of quercetin used was same as those of the test compounds. The a-amylase inhibition percentage was calculated as follows: % inhibition = 100 _ (X2 sample _ X1 sample/X2 control _ X1 control) Â 100 where X1 is the absorbance of the initial reading and X2 is the absorbance of the final reading. The results were expressed as IC 50 determined from the curve.
In vitro inhibition of a-glucosidase activity The a-glucosidase inhibitory activity of the tested compounds was evaluated according to the method described by Andrade-Cetto and collaborators 45 based on the release of 4-nitrophenol a-D-glucopyranoside (4 NPGP). Briefly, 20 ml of different concentrations (ranging from 0 to 50 mg/ml) of each compound, the appropriate solvent, or quercetin (positive control) was mixed with 180 ml of the a-glucosidase enzyme from Saccharomyces cerevisiae (Sigma) and the obtained mixture was incubated at 37 C for 2 min, followed by additional incubation for more than 15 min at 37 C after the addition of 150 ml of the colour reagent NPGP. The colorimetric assay included 2 U of a-glucosidase, 5 mM of 4-NPGP, and 10 mM potassium phosphate buffer, pH 6.9. The concentration of quercetin used was identical to that of the tested compounds. The reading assay was performed using a microplate reader at 405 nm. The a-glucosidase inhibition percentage was calculated as follows: % inhibition = 100 _ (X2 sample _ X1 sample/X2 control _ X1 control) Â 100 where X1 is the absorbance of the initial reading and X2 is the absorbance of the final reading, control is the absorbance of the assay with the appropriate solvent. The results were expressed as IC 50 determined from the curve.
In vitro inhibition of xanthine oxidase
The xanthine oxidase inhibitory activities of the examined chemical compounds were determined by following the formation of uric acid from xanthine according to the reported method by Bondet and co-workers 46 . Forty microliters xanthine oxidase (667 mM) and 15 ml of each compound (0-150 mg/ml), allopurinol (positive control), or appropriate solvent (negative control) were added to each microplate well and preincubated for 5 min at 37 C. Then, 95 ml of reagent 1 (mixture of hydroxylamine (0.2 mM), EDTA (0.1 mM), and xanthine oxidase (667 mM) in 50 mM phosphate buffer solution (pH 7.5) were added to the reaction mixture and incubated at the same temperature for 30 min. Subsequently, the absorbance was measured at 295 nm using a microplate reader. Finally, after addition of 150 ml of uric acid reagent, the absorbance was measured again. The concentration of allopurinol used was same as that of the tested compounds. Xanthine oxidase inhibition was calculated as follows: % inhibition = 100 _ (X2 sample _ X1 sample/X2 control _ X1 control) Â 100 where X1 is the absorbance of the initial reading and X2 is the absorbance of the final reading. The results were expressed as IC 50 determined from the curve. 
Results and discussion
Chemistry
The main targets of this investigation were 3H-quinazolin-4-one derivatives possessing general structure 1.
Two synthetic approaches were used for the synthesis of these scaffolds.
The first synthetic approach featured the preparation and chemical transformations of the key intermediates benzo[d] [1, 3] oxazin-4-one derivatives 3a-d to various 3H-quinazolin-4-one derivatives as depicted in Scheme 1.
The conventional methods available for the synthesis of compounds 3a-d via cyclocondensation of anthranilic acid derivatives 2a-d with acetic anhydride [26] [27] [28] were time consuming, therefore, these compounds were synthesised using the more efficient microwave-assisted method. Fusion of oxazinones 3a-c with 3,4,5-trimetrhoxyanline 4 32,33 yielded 2-methyl-3-(3,4,5-trimethoxy-phenyl)-3H-quinazolin-4-one derivatives 5a-c. The assigned molecular structures of these new quinazolin-4-one derivatives were in full agreement with their spectroscopic and elemental analyses. Thus the IR spectrum (KBr) of compound 5c, for example, displayed absorption bands at v max 3075, 2934; 2839, 1680, 1598; 1504 and 834 cm À1 for aromatic-CH, aliphatic-CH, the carbonyl group, C ¼ C and C-Cl, respectively. The 1 H NMR spectrum of compound 5c revealed the presence of five aromatic protons, which were displayed as; a one proton doublet signal at d 8.18 ppm with coupling constant J of 2.4 Hz corresponding to CH 5 -quinazolin-4-one, a one-proton double-doublet signal at d 7.69 ppm with coupling constant J of 8.7, 2.4 Hz due to CH 7 -quinazolin-4-one, a one-proton doublet signal at d 7.60 ppm with coupling constant J of 8.7 Hz corresponding to CH 8 -quinazolin-4-one, and a two-protons singlet peak at d 6.51 ppm, which was attributed to the two methine protons of 3,4,5-trimethoxyphenyl moiety (H2 ' and H 6' ). The nine protons of the three methoxy groups were displayed as a three-protons singlet at d 3.92, and a six-protons singlet at d 3.88 ppm. Finally, the three protons of the methyl group were characterised by a three-protons singlet signal at d 2.32 ppm. Moreover, the 13 C NMR spectrum also confirmed the assigned structure based on the emergence of fifteen spectral lines at d 29, 30 , which were converted to certain novel Schiff bases 8a-j via condensation with a series of aryl aldehydes 7a-e in absolute ethanol containing catalytic amount of glacial acetic acid 34 . The structures of the new Schiff's bases were verified by their IR, 1 H NMR, 13 C NMR, mass spectroscopic (MS) data, and CHN analyses. The IR spectra of compounds 8a-j indicated disappearance of the stretching bands of the amino groups in 3-aminoquinazolin-4-one derivatives 6a,b. 
Furthermore, the amino group of 3-amino-2-methyl-3H-quinazolin-4-one 6a was transformed to the corresponding carbamate group via direct nucleophilic substitution reaction for isobutyl chloroformate 9 35 to yield the new carbamate derivative 10. The structure of the latter product was established on the basis of its IR, 1 H NMR, 13 C NMR, MS and HCN elemental analyses. The IR spectrum displayed the characteristic stretching absorption bands at v max 3223, 1755, and 1694 cm À1 indicating the presence of NH and two C ¼ O groups. The 1 H NMR spectrum of compound 10 was characterised by the presence of a one-proton broad singlet peak at d 7.62 ppm due to NH group, in addition to the presence of a two-protons apparent singlet signal, a one-proton multiplet, and a six-protons doublet signal with coupling constant value J of 6.0 Hz at d 4.00, 1.96-1.93 and 0.94 ppm, respectively corresponding to (O-CH 2 -CH-(CH 3 ) 2 ) isobutoxy group. Moreover, the 13 The second synthetic approach for preparation of 3H-quinazolin-4-one derivatives involved the synthesis of compounds 15a-f via nucleophilic attack by 2-mercapto-3-phenyl-3H-quinazolin-4-one derivatives 13a',b' on 4-chlorobenzyl chloride 14a or chloroacetamide derivatives 14b,c 37, 38 to yield compounds 15a-f by adapting modified procedure to what was reported by Salman et al. 39 as illustrated in Scheme 2. Structures of the new quinazolinone derivatives 15b and 15d,f were verified based on their respective IR, 
Biological evaluation
Effects of the synthesised 3H-quinazolin-4-one derivatives on cell viability of human colorectal cancer cell lines HT-29 and SW620 As CRC starts with initial benign stages advanced to late stage leading to metastasis. Therefore, two human CRC cell lines which belong to two different stages namely, HT-29 which is derived from adenocarcinoma CRC and SW620 which is derived from metastatic site were selected for in vitro evaluation of the cytotoxicity (30 lg/ml) of twenty-one compounds incorporating the 3H-quinazolin-4-one scaffold.
Cell viability was monitored using the MTT assay and the results are presented in Supplementary Figure 1 . Compared to the negative control, and the positive control (5-FU), the synthesised 3H-quinazolin-4-one derivatives displayed varied degrees of cytotoxicity against the examined colorectal cell lines. Eight out of all the examined compounds showed significant decrease in cell viability. In one hand, compound 15c inhibited only HT-29 cell line (47.5% viability) whereas compound 5b inhibited only SW620 cell line (46.6% viability). On the other hand, six compounds namely, 8a, 8f, 8j, 15a, 15b, and 15d, were potently capable of inhibiting cell viability of both human CRC cell lines. Compound 15d was the most active in this set reducing the cell viabilities of HT-29 and SW620 cells lines to 38% and, 36.7%, compared to 5-FU which demonstrated cell viabilities of 65.9 and 42.7%, respectively. Hence, compound 15d was selected for further mechanistic studies. The results indicated that compound 15d inhibited cell viability in a dose-dependent manner. The IC 50 for 15d was $20 mg/ml for HT-29 and SW620 cells ( Supplementary Figures 2 and 3) . These results were again confirmed using the xCELLigence RTCA system, which measures the cytotoxic effect of inhibitors in real time at different time points and 15d was found to inhibit the cell proliferation in human CRC HT-29 and SW620 cell lines in dose-and time-dependent manner (Supplementary Figures 4 and 5) .
Evaluation of anti-apoptotic protein expression by compound 15d SW620 cells were treated with various concentrations of 15d for 24 h. Subsequently, cell lysates were immunoblotted with the indicated antibodies in order to investigate the mechanism via which this compound inhibited cell viability of human CRC cells. Results shown in Supplementary Figure 6 indicated that 15d inhibited the anti-apoptotic proteins, Bcl2 and BclxL. These findings demonstrate that compound 15d inhibited the cell viability of human CRC cells by down regulating the expression of Bcl2 and BclxL and triggering the apoptotic pathway.
In vitro evaluation of antiphospholipase A 2 (PLA 2 ) and antiproteases activities of the synthesised 3H-quinazolin-4-one derivatives As inflammation is associated with several types of cancers via influencing growth, apoptosis, and proliferation of cancer and stromal cells, the synthesised 3H-quinazolin-4-one derivatives were further screened to evaluate their antiphospholipases activities against proinflammatory enzymes implicated in cancer namely, hGIIA, hGV, and X 10 . In addition, the inhibitory activity of these compounds towards the allergen and inflammatory PLA 2 from honey bee venom (Apis mellifera, AmPLA 2 ) 47 and proinflammatory, heamolytic, myotoxic and neurotoxic Cobra (Naja mosambique mosambique) venom PLA 2 (NmPLA 2 ) 48 were evaluated by determining their IC 50 values. Results (Supplementary Table 1) revealed that six compounds, namely, 5a, 8c, 8d, 8j, 15a, and 15d displayed the most promising potency in inhibiting the catalytic activity of the studied hG-IIA, with IC 50 values ranging from 5. 75 ± 1.06 to 8.60 ± 0.56 mg/ml compared to that recorded with oleanolic acid which was used as a standard drug (5.25 ± 0.35 mg/ml). Among these compounds, 8d exhibited the lowest IC 50 value (5. 75 ± 1.06 mg/ml).
The anti-PLA 2 hGV data showed that three compounds; 5a, 8d, and 8j inhibited the enzyme with IC 50 values ranging from 6.25 ± 0.78 to 9.60 ± 0.85 mg/ml compared to the value recorded with the standard drug (oleanolic acid, IC 50 ; 7.50 ± 0.71 mg/ml). Amongst them, compound 8j (IC 50 ; 6.25 ± 0.78 mg/ml), was being more potent than the reference drug.
The analysis of the inhibitory potency of the examined compounds against PLA 2 hG-X showed that compounds; 5a, 5 b, 5c, 8d, 8j, 10, 15a, and 15e inhibited the enzymatic activity with IC 50 values ranging from 6.60 ± 0.85 to 9.50 ± 0.71 mg/ml. It worth to note that compounds 8d, 15a, and 15e exhibited lowered IC 50 values than the reference drug (IC 50 ; 7.55 ± 0.64 mg/ml).
Amongst the tested 3H-quinazolin-4-one derivatives which exhibited inhibitory activity against NmPLA 2 were compounds; 5a, 5b, 5c, 8c, 8d, 8e, 8f, 15a, and 15d with IC 50 values ranging from 4.15 ± 0.50 to 8.50 ± 2.12 mg/ml compared to oleanolic acid (IC 50 ; 4.90 ± 0.42 mg/ml). Interestingly, compound 5b demonstrated the lowest IC 50 which is also lower than that of the reference drug fusspot.
Finally, 13 compounds namely, 5a, 5b, 5c, 8b, 8c, 8d, 8e, 8f, 8i, 10, 15a, 15d, and 15e effectively suppressed AmPLA 2 with IC 50 values ranging from 4.20 ± 0.57 to 9.40 ± 0.85 mg/ml compared to the IC 50 4.20 ± 0.42 mg/ml value of oleanolic acid. Based on these results, AmPLA 2 appears to be the maximally affected phospholipase by the synthesised compounds with compound 8f (IC 50 ; 4.20 ± 0.57 mg/ml) demonstrating inhibitory activity equivalent to that of the reference drug.
Similarly, the inhibitory potency of the selected 3H-quinazolin-4-one derivatives against five proteases namely, cathepsin-B, collagenase, thrombin, elastase, and trypsin was quantified by measuring and comparing the IC 50 values produced by these compounds relative to the value produced by the protease inhibitor cocktail. The results of anti-proteases shown in Supplementary Table 2 indicated that compounds 8j and 15e were being the most active inhibitors against protease cathepsin-B with IC 50 values of 1.40 ± 0. 06 and 1.60 ± 0.07 mg/ml respectively compared to cocktail (IC 50 ; 0.175 ± 0.04 mg/ml).
Furthermore, compounds 8b, 8d, and 15e were found to be the most active in suppressing the collagenase activity with IC 50 values ranging from 3.00 ± 0.01 to 4.50 ± 0.71 mg/ml compared to cocktail (IC 50 ; 0.15 ± 0.07 mg/ml) with compound 8d exhibiting the lowest IC 50 value.
The highest anti-thrombin activity was demonstrated by compounds 5b, 5c, 8e, 10, and 15b, with IC 50 values ranging from 0.90 ± 0.14 to 2.50±0.71 mg/ml, with 5b demonstrating the lowest IC 50 compared to cocktail (IC 50 ; 0.25 ± 0.07 mg/ml).
The highest anti-elastase activity was demonstrated by compounds 5b, 5c, 8e, 10, and 15b, with IC 50 values ranging from 0.65 ± 0.02 mg/ml (compound 15b) to 1.75 ± 0.05 mg/ml (compound 5c) compared to that of cocktail (IC 50 ; 0.125 ± 0.04 mg/ml).
Finally, the lowest IC 50 values ranging from 0.50 ± 0.00 to 2.25 ± 0.04 mg/ml against trypsin were demonstrated by compounds 5b, 5c, 8e, 10, and 15 b, with compound 15b displaying the lowest IC 50 compared to that of the reference drug (IC 50 ; 0.215 ± 0.04 mg/ml).
In vitro evaluation of inhibitory activities of 3H-quinazolin-4-one derivatives against enzymes implicated in metabolic syndrome Considering an interactive relationship between diabetes and cancers, the in vitro inhibitory potential of the prepared 3H-quinazolin-4-one derivative against a-amylase, a-glucosidase, and xanthine oxidase (enzymes related to metabolic syndrome) was investigated.
The IC 50 values exhibited by the chemical compounds against a-amylase activity are shown in Supplementary Table 3 , which indicated that compounds 8d, 8h, 8j, 15a, 15b, 15e, and 15f, were more potent in suppressing the enzyme with IC 50 values ranging from 94.00 ± 2.83 mg/ml (compound 15b) to 121.00 ± 9. 90 mg/ml (compound 15e) than quercetin the reference drug (IC 50 123.0 ± 2.83 mg/ml).
In addition, compounds 8g (IC 50 3.25 ± 0.35 mg/ml), 8h (IC 50 3.05 ± 0.21 mg/ml), and 8i (IC 50 3.45 ± 0.64 mg/ml) were more potent in inhibiting a-glucosidase activity than quercetin (IC 50 3.80 ± 0.28 mg/ml) (Supplementary Table 4) .
Although none of the tested compounds was more effective than allopurinol (reference drug) in inhibiting xanthine oxidase (XO) activity (Supplementary Table 5 ) (IC 50 0.65 ± 0.07 mg/ml), compound 8f (IC 50 3.00 ± 1.41 mg/ml) was the most active among the tested compounds.
Conclusions
A series of 25 compounds incorporating the 3H-quinazolin-4-one scaffold were synthesised , 20 of which were new and fully characterised. Twenty-one compounds were screened for their cytotoxicity on human CRC cell lines HT-29 and SW620 using the MTT assay. Six compounds namely, 8a, 8f, 8j, 15a, 15b, and 15d potently reduced viability of both cell lines, with 15d the most active in this set displaying residual viability 38%, 36.7% against HT-29 and SW620 cells lines, respectively. Further mechanistic studies using 15d revealed that this compound inhibited the cell proliferation of HT-29 and SW620 cell lines in a dose-and timedependent manner with IC 50 values $20 mg/ml. Evaluation of antiapoptotic protein expression by compound 15d revealed that it reduced the viability of the used human CRC cells by down regulating the expression of Bcl2 and BclxL.
Based on these results, 15d could be considered as an attractive candidate for further investigations as a potential anticancer agent. Furthermore, the prepared compounds were screened for their inhibitory activities against certain phospholipases including, hG-IIA, hG-V, hG-X, NmPLA 2 , and AmPLA 2 , and five proteases namely, cathepsin-B, collagenase, thrombin, elastase, and trypsin, in addition to three enzymes involved in metabolic syndrome namely, a-amylase, a-glucosidase, and xanthine oxidase. Although none of the tested compounds showed good antiprotease activity, six compounds 8j, 8d/15a/15e, 5b, and 8f demonstrated higher antiphospholipases potential against proinflammatory isoforms hGV, hG-X, NmPLA 2 and AmPLA 2 than oleanolic acid, which was used as reference drug.
Therefore, these compounds would be of interest as preclinical candidates in trials for anticancer and anti-inflammatory drugs.
All the tested compounds were inactive against xanthine oxidase, whereas compounds 8d, 8h, 8j, 15a, 15b, 15e, and 15f elicited higher a-amylase inhibition than the reference drug quercetin. Furthermore, compounds 8g, 8h, and 8i were more potent in inhibiting a-glucosidase activity than the reference drug allopurinol. Consequently, these compounds can be considered as potential targets that can be further investigated for developing novel anti-diabetes mellitus (DM) drugs.
